TuHURA Biosciences Inc

With the transition into Stage 3 distribution and the long-term downtrend intact, HURA’s medium-term bias is bearish. Price has failed to clear the flattened 9/21 EMAs and was rejected at this resistance zone on elevated volume. Short-term execution favors immediate sell-side participation on this clear rejection. Under a speculative framework, clear structural asymmetry justifies a Sell Now posture, with the downtrend confirmed unless HURA can reclaim key moving average levels.

• ↑IND filed for TBS-2025 enables Phase 1b/2 AML study.
• ↑Strong growth outlook aligns with rising precision oncology demand.
• ↓Negative profitability and earnings yield hinder shareholder returns.